$360,000.00 in Sales Expected for VBI Vaccines Inc (NASDAQ:VBIV) This Quarter

Equities analysts expect VBI Vaccines Inc (NASDAQ:VBIV) to post $360,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for VBI Vaccines’ earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $210,000.00. VBI Vaccines reported sales of $650,000.00 during the same quarter last year, which indicates a negative year over year growth rate of 44.6%. The company is expected to issue its next earnings results on Wednesday, November 4th.

According to Zacks, analysts expect that VBI Vaccines will report full year sales of $1.42 million for the current financial year, with estimates ranging from $1.13 million to $1.70 million. For the next financial year, analysts anticipate that the firm will post sales of $5.26 million, with estimates ranging from $4.10 million to $6.42 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings results on Friday, July 31st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.86 million. VBI Vaccines had a negative net margin of 2,467.47% and a negative return on equity of 46.47%.

VBIV has been the topic of a number of analyst reports. BidaskClub upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research report on Friday, September 18th. Zacks Investment Research downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Saturday, July 11th. Raymond James upgraded shares of VBI Vaccines from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $8.00 to $9.00 in a research report on Wednesday, August 26th. Oppenheimer restated a “buy” rating and set a $8.00 target price on shares of VBI Vaccines in a report on Thursday, August 27th. Finally, ValuEngine downgraded shares of VBI Vaccines from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $5.30.

A number of hedge funds have recently made changes to their positions in the business. Oppenheimer & Co. Inc. raised its holdings in shares of VBI Vaccines by 64.8% in the first quarter. Oppenheimer & Co. Inc. now owns 26,200 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 10,300 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of VBI Vaccines in the second quarter valued at approximately $30,000. Prudential Financial Inc. acquired a new stake in shares of VBI Vaccines in the second quarter valued at approximately $31,000. Royal Bank of Canada raised its holdings in shares of VBI Vaccines by 832.1% in the first quarter. Royal Bank of Canada now owns 35,437 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 31,635 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of VBI Vaccines in the first quarter valued at approximately $35,000. Hedge funds and other institutional investors own 42.59% of the company’s stock.

Shares of NASDAQ:VBIV traded down $0.12 during mid-day trading on Monday, reaching $2.96. The stock had a trading volume of 6,925,462 shares, compared to its average volume of 10,427,736. The firm has a market cap of $684.35 million, a PE ratio of -11.38 and a beta of 1.79. The firm has a 50 day simple moving average of $3.55 and a two-hundred day simple moving average of $2.62. The company has a current ratio of 5.86, a quick ratio of 5.77 and a debt-to-equity ratio of 0.13. VBI Vaccines has a twelve month low of $0.47 and a twelve month high of $6.93.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Further Reading: Understanding Analyst Ratings

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.